🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to health experts.

A Global Public Health Issue

Cases of gonorrhoea are increasing globally, with estimates suggesting in excess of 82 million new cases each year. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the face of increasing worldwide cases, escalating drug resistance and the very limited treatment choices at this time.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". Recent surveillance found that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Gain Authorization

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is also used to treat urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This approval marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Data and Worldwide Availability

As per findings published in a major medical journal, the new drug cured more than 90% of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which uses two antibiotics. The study involved over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have shared hope. The availability of a easy-to-administer therapy such as this is described as a "game-changer" for gonorrhoea control. This is deemed essential to alleviate the strain of the infection for individuals and to prevent the spread of untreatable gonorrhoea around the world.